Does Sermorelin Reduce Visceral Fat?

Does sermorelin reduce visceral fat? This question is increasingly asked as interest in peptide therapies grows, but the clinical evidence remains limited. Sermorelin is a synthetic analogue of growth hormone-releasing hormone that stimulates the pituitary gland to produce endogenous growth hormone. While growth hormone plays a recognised role in fat metabolism and body composition, sermorelin holds no MHRA marketing authorisation for visceral fat reduction or weight management in adults. This article examines what the current evidence shows, how sermorelin works, and what MHRA-authorised options are available in the UK for reducing visceral fat safely and effectively.

What is sermorelin and how does it work in the body?

Sermorelin is a synthetic peptide comprising the first 29 amino acids of GHRH that stimulates the anterior pituitary to release growth hormone in a pulsatile, physiological pattern. It has no MHRA marketing authorisation for body composition or weight management in adults.

Sermorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and secrete endogenous growth hormone. It consists of the first 29 amino acids of naturally occurring GHRH and acts on specific receptors in the anterior pituitary, prompting a pulsatile release of growth hormone that broadly mirrors the body's own physiological pattern.^[3]

Growth hormone plays a well-established role in metabolism, including the regulation of fat distribution, lean muscle maintenance, and energy utilisation. As people age, natural growth hormone secretion declines, a process sometimes referred to as somatopause, and this decline has been associated with increases in body fat, particularly in the abdominal region.^[1][2] Sermorelin is proposed to counteract this by restoring more youthful growth hormone levels indirectly, rather than by administering exogenous growth hormone directly.

Sermorelin does not hold a marketing authorisation from the MHRA for use in adults for body composition or weight management purposes, and there is no UK SmPC for these indications. Where a prescriber chooses to use an unlicensed medicine outside a clinical trial, this constitutes unlicensed use and must occur under the prescriber's responsibility via lawful unlicensed supply routes, such as MHRA-regulated Specials or licensed import. This is not a routine pathway and does not apply to self-sourcing from unregulated suppliers. Patients should be aware of this distinction before seeking access to sermorelin.

What does the current evidence say about sermorelin and body composition?

Current evidence is limited to small, short-duration studies in selected populations, and no large randomised controlled trials support sermorelin as an effective treatment for visceral fat reduction. NICE and NHS guidance do not recommend it for this purpose.

The current clinical evidence on sermorelin and visceral fat reduction in adults is limited, and no robust, large-scale randomised controlled trials have established it as an effective treatment for this purpose. Most of the available data come from small studies, short-duration trials, or research conducted in specific populations such as adults with diagnosed growth hormone deficiency, rather than in the general population seeking weight management.

Some earlier research examining GHRH analogues more broadly suggested that stimulating endogenous growth hormone secretion may modestly improve body composition, including reductions in fat mass and increases in lean body mass. However, these findings have not been consistently replicated, and the clinical significance of any observed changes in visceral fat specifically remains uncertain. The studies involved are generally small, of short duration, and conducted in selected populations, which limits how far their results can be generalised.

Growth hormone itself, when administered directly, has demonstrated effects on lipolysis and fat redistribution in people with confirmed growth hormone deficiency, as described in Endocrine Society guidance on adult growth hormone deficiency.^[4][5] However, this does not automatically translate to meaningful visceral fat reduction in otherwise healthy adults using a secretagogue such as sermorelin. The indirect mechanism of action, relying on the pituitary's capacity to respond, introduces additional variability in outcomes.

Given the absence of MHRA-authorised indications for sermorelin in adult body composition management, there are no NICE guidelines or NHS recommendations supporting its use for visceral fat reduction. Patients and clinicians should interpret any promotional claims about sermorelin and fat loss with caution, and evidence should be evaluated critically against the quality and size of the underlying studies.

What other options exist for reducing visceral fat in the UK?

MHRA-authorised pharmacological options for chronic weight management include semaglutide, tirzepatide, liraglutide, orforglipron, and orlistat, used alongside lifestyle changes. NICE guidance supports dietary modification, increased physical activity, and behavioural support as the foundation of treatment.

Visceral fat refers to fat stored around the internal organs in the abdominal cavity. It is associated with increased risk of type 2 diabetes, cardiovascular disease, and metabolic syndrome. In clinical practice, waist circumference and waist-to-height ratio are commonly used to assess abdominal adiposity; NHS guidance suggests a waist circumference above 94 cm in men or 80 cm in women indicates increased risk, with higher thresholds indicating substantially increased risk.^[6]

Reducing visceral fat is best achieved through a combination of sustained lifestyle changes. NICE guidance consistently supports dietary modification, increased physical activity, and behavioural support as the foundation of any weight management approach. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults, and dietary advice should align with the NHS Eatwell Guide, which emphasises reducing ultra-processed foods and refined carbohydrates in favour of vegetables, wholegrains, and lean protein.^[7][8]

For people with a body mass index (BMI) above defined thresholds, or those with weight-related comorbidities, licensed pharmacological treatments may be appropriate alongside lifestyle intervention. In the UK, options authorised by the MHRA for chronic weight management include:

• Semaglutide (Wegovy), a GLP-1 receptor agonist available as a subcutaneous injection, with doses up to 2.4 mg weekly and a higher-dose 7.2 mg strength also authorised by the MHRA

• Tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist authorised in the UK both for type 2 diabetes and for chronic weight management^[13][14]

• Liraglutide (Saxenda), a once-daily GLP-1 receptor agonist licensed for weight management

• Orforglipron (Foundayo), an oral GLP-1 receptor agonist authorised by the MHRA for chronic weight management^[17]

• Orlistat, a lipase inhibitor available on prescription and in lower doses over the counter

These medicines work through different mechanisms and have been evaluated in clinical trials that include measures of body fat distribution, including visceral fat, alongside overall weight outcomes. NICE technology appraisals and NHS commissioning guidance set out eligibility criteria and the role of these treatments within tiered weight-management services. For some patients, referral to a specialist weight-management service or consideration of bariatric surgery may be appropriate; a GP can advise on local pathways and referral criteria.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support. Clinically appropriate options may be considered following a consultation; eligibility and suitability are determined on an individual basis following a clinical assessment, and local ICB commissioning decisions affect NHS availability.

Can sermorelin actually help reduce visceral fat?

There is currently insufficient clinical evidence to conclude that sermorelin meaningfully reduces visceral fat in adults without confirmed growth hormone deficiency. MHRA-authorised treatments and structured lifestyle change remain the recommended evidence-based approaches.

Sermorelin may have a theoretical basis for influencing body composition through its stimulation of endogenous growth hormone, but there is currently insufficient clinical evidence to conclude that it meaningfully reduces visceral fat in adults without confirmed growth hormone deficiency. The mechanistic rationale is plausible, in that growth hormone promotes lipolysis and can shift fat distribution away from visceral depots, but plausibility alone does not constitute clinical proof.

Because sermorelin has no MHRA-licensed indication for body composition or visceral fat reduction in the UK, it is not available through standard NHS or routine regulated private pathways for this purpose. Outside an authorised clinical trial, any prescribing of sermorelin for these uses would constitute unlicensed use and should only occur, if at all, under specialist oversight via lawful unlicensed supply routes under the prescriber's responsibility. This is not a routine or widely available pathway. Patients should not seek sermorelin through unregulated online sources, as product quality, dosing accuracy, and safety monitoring cannot be assured; to verify that an online pharmacy is legitimate, check the GPhC register at pharmacyregulation.org.

For those concerned about visceral fat and its associated health risks, including increased likelihood of type 2 diabetes, cardiovascular disease, and metabolic syndrome, the most evidence-based approach remains structured lifestyle change supported where appropriate by MHRA-authorised pharmacological treatment.^[22] A GP can assess whether further investigation or referral to a specialist weight management service is appropriate.

If you experience unexplained weight gain, particularly around the abdomen, alongside other symptoms such as fatigue or changes in blood glucose, speak to your GP rather than seeking unlicensed treatments independently. Suspected adverse effects from any medicine, including those used outside their licensed indication, can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions